Posted By Syapse 04/05/2017

Partnership Strives to Improve Care for Cancer Patients in Southeastern U.S. Miami, Fla. (April 5, 2017) – Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, and Syapse, a market leader in precision oncology solutions, today announced that they will team up to launch a new precision medicine initiative at Sylvester to help make personalized cancer care in South Florida and throughout the Southeastern U.S. more effective. By partnering with Syapse, Sylvester physicians will be able to more efficiently deliver personalized care that matches patients with targeted, cutting-edge therapies based on the clinical and molecular profile of the patient, leading to improved survival rates and better health outcomes.

read more
Posted By Syapse 03/15/2017

Former RelayHealth Executive to Lead Rapidly Growing Company

Posted By Syapse 09/19/2016

SAN FRANCISCO, Calif. and ENGLEWOOD, Colo. – September 19, 2016 – Dignity Health and Catholic Health Initiatives (CHI), two of the nation's largest health systems, announced today the launch of the Precision Medicine Alliance LLC that will offer patients from both health care systems faster and more accurate diagnostic and treatment protocols based on their genetic and molecular profile information. The program will be available at nearly 150 hospitals and care centers across the U.S., serving approximately 12 million patients annually, creating the largest community-based precision medicine program in the country.

read more
Posted By Syapse 06/29/2016

PALO ALTO, Calif.; SALT LAKE CITY, Utah; RENTON, Wash.; STANFORD, Calif. June 29, 2016 - An initiative to end cancer is getting a boost from additional efforts from a newly formed data sharing network. The Oncology Precision Network (OPeN) is announcing additional commitments to bring access to precision medicine and data sharing to additional health systems and cancer patients across the country. The commitment, taking place in conjunction with the Cancer Moonshot Summit in Washington, DC on June 29, in being announced in advance by the White House in a blog post on the Cancer Moonshot Publication.

read more
Posted By Syapse 06/29/2016

WASHINGTON, D.C.; PALO ALTO, Calif.; ENGLEWOOD, Colo., June 29, 2016 - Catholic Health Initiatives (CHI), the nation's second-largest nonprofit health system, and Syapse, the leading precision medicine software company, are announcing today the launch of a precision oncology program to serve patients across CHI, which operates 103 hospitals and hundreds of other care sites across a system in 18 states that includes four academic health centers and major teaching hospitals.

read more
Posted By Syapse 06/29/2016

WASHINGTON, D.C., June 29, 2016 - Henry Ford Health System, one of the nation's leading comprehensive and integrated health systems, and Syapse, the leading precision medicine software company, are announcing today the launch of an oncology precision medicine program to revolutionize cancer care in the greater Midwest. With the goal of increasing access to the best care for all patients, the Henry Ford-Syapse partnership will bring world class, targeted cancer treatments to this national destination referral center in Michigan and will continue to offer a bright beacon of hope to underserved populations in Detroit.

read more
Posted By Syapse 06/06/2016

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial. Since opening on March 14, 2016, 18 participants have enrolled and are receiving study treatment, and 31 more have provided consent and are in, or have completed, the screening process. These numbers continue to grow daily.

read more
Posted By Jordan 06/02/2016

Intermountain Healthcare, Stanford Cancer Institute, and Providence Health & Services are founding health systems members of the Oncology Precision Network. PALO ALTO, Calif.; SALT LAKE CITY, Utah; RENTON, Wash.; STANFORD, Calif., June 2, 2016 - Intermountain Healthcare, Stanford Cancer Institute, Providence Health & Services, and Syapse joined together today to announce a new consortium to advance cancer care through data sharing and increase access to clinical trials. Responding to Vice President Joe Biden’s Cancer Moonshot Initiative, the Oncology Precision Network (OPN) will share, as appropriate, aggregated cancer genomics data through an advanced software platform, rapidly bringing the most promising treatment insights to cancer patients and physicians.

read more
Posted By Andro 03/14/2016

ALEXANDRIA, Va. — The American Society of Clinical Oncology (ASCO) today announced it has begun recruiting patients with advanced cancer for its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study. The trial will evaluate molecularly-targeted cancer drugs and collect data on clinical outcomes to help learn additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA). Patients enrolled in the study will have access to these cancer drugs at no cost.

read more
Posted By Jordan 02/26/2016

SALT LAKE CITY, Utah and PALO ALTO, Calif., February 26, 2016 – On February 25th, leaders from Intermountain Healthcare, a not-for-profit health system of 22 hospitals based in Salt Lake City and Syapse, the leading provider of precision medicine software, participated in the White House Precision Medicine Initiative Summit. The event highlighted the achievements of pioneers in bringing precision medicine into clinical practice, and the White House released the following statement describing the commitment of of Intermountain and Syapse to further the progress of precision medicine:

read more
Posted By Jordan 02/18/2016

PALO ALTO, Calif., February 18, 2016 – Syapse, the leader in precision medicine software, announced today the creation of the Syapse Global Partner Program (GPP), which will leverage best-of-breed partners to enhance and accelerate the implementation of the Syapse Precision Medicine Platform at healthcare organizations globally.

read more
Posted By Jordan 01/12/2016

PALO ALTO, Calif. and CLAYTON, Mo., January 12, 2016 – Syapse, the leader in precision medicine software, has completed the first close of a $25 million Series C funding round. The financing round is being led by Ascension Ventures, a subsidiary of Ascension, the nation's largest non-profit and Catholic health system. Existing investors Social Capital Partnership and Safeguard Scientifics also participated in this new funding round.

read more
Posted By Syapse 11/18/2015

IRVING, Texas and PALO ALTO, Calif., November 18, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Syapse, the leading provider of precision medicine software, announced a collaboration to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network™ (COE Network). The COE Network consists of leading cancer centers that have demonstrated a commitment to precision medicine and are working collaboratively to establish improved standards of care for molecular tumor profiling in oncology. Integration of Caris Molecular Intelligence®, Caris’ panomic, comprehensive tumor profiling service, with the Syapse Precision Medicine Platform, will provide a powerful real-time, point-of-care clinical decision support system to enable more informed treatment decisions for each individual patient. Participating COE Network sites can use the integrated decision support system, and may use Syapse to further support their complete precision medicine workflows.

read more
Posted By Syapse 11/12/2015

WASHINGTON, D.C. – This year approximately 12,000 individuals in the US and tens of thousands more around the globe, including 35,000 in China alone, will receive a diagnosis of glioblastoma multiforme (GBM) from their doctors. GBM is the most common adult brain tumor and it is highly aggressive. In fact, fifty percent of GBM patients will survive for a year or less. Five-year survival for GBM is less than two percent – and, unfortunately, these dismal statistics have not changed for decades.

Posted By Jordan 10/29/2015

Integrated molecular testing and clinical decision support solutions streamline the precision medicine workflow for healthcare systems with internal labs ST. LOUIS, Mo. and PALO ALTO, Calif., October 29, 2015 – PierianDx, makers of the leading bioinformatics platform for clinical genomics testing, and Syapse, the leading provider of precision medicine software, announced a partnership that will accelerate the adoption of precision medicine by healthcare systems. The companies will provide functional integration between PierianDx’s Clinical Genomicist Workstation™ and Syapse Precision Medicine Platform in order to streamline the end-to-end genomic testing workflow for hospitals with in-house labs.

read more
Posted By Andro 06/04/2015

SIOUX FALLS, S.D., and PALO ALTO, Calif., June 4, 2015 – Sanford Health, the largest rural, not-for-profit health care system in the United States, announced the first enterprise-wide availability of real-time drug dosing and order modification alerts tailored to a patient’s genetic profile within a commercial EHR system. Sanford Health has automated pharmacogenetic clinical decision support and the internal test process using Syapse Precision Medicine Platform.

read more
Posted By Andro 06/01/2015

CHICAGO, Ill., June 1, 2015 – The American Society of Clinical Oncology (ASCO) today announced its first-ever clinical trial that will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect “real-world” data on clinical outcomes to help learn the best uses of these drugs outside of indications approved by the Food and Drug Administration (FDA). Plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study, including the participation of major pharmaceutical companies that will contribute free drugs, were released in a news briefing at the Society’s 2015 Annual Meeting in Chicago.

read more
Posted By Andro 06/01/2015

PALO ALTO, Calif., June 1, 2015 – Syapse, the leading provider of precision medicine software, announced today that its Syapse Precision Medicine Platform was selected by the American Society of Clinical Oncology (ASCO) to automate clinical workflows for the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. This groundbreaking clinical trial will provide qualifying cancer patients who lack standard treatment options access to molecularly-targeted medications outside of their Food and Drug Administration (FDA) approved indications, and will track treatment courses and outcomes. Using the Syapse platform, practices participating in TAPUR can integrate study participants’ genomic profile, treatment history, and clinical outcomes and report the data to the researchers. The Syapse platform will also support the work of the TAPUR Molecular Tumor Board.

read more
Posted By Andro 05/29/2015

SALT LAKE CITY, Utah, May 29, 2015 – Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Genomics reveal that precision medicine can improve survival in advanced cancer patients – and do so without increasing costs. While the results affect only stage four cancer patients in the latter weeks of life, the improvement is pronounced and lends hope that further improvement can be realized going forward. The studies will be published in abstract form through the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

read more
Posted By Andro 05/12/2015

Our own Founder & President Jonathan Hirsch appeared this morning on Fox Business' Opening Bell with Maria Bartiromo to discuss how Syapse is helping our customers use tumor profiling and targeted therapy to increase cancer patient survival.

read more